Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions

Abstract

Purpose: To evaluate the rate and dose response of brachial plexus toxicity post stereotactic body radiation therapy (SBRT) of apically situated lung lesions.

Material/methods: We retrospectively identified all patients with apically located tumors, defined by the epicenter of the tumor being located superiorly to the aortic arch, and treated with SBRT between 2008 and 2013. Patients with a shorter follow-up than 6 months were excluded. Primary aim was to evaluate radiation-induced brachial plexopathy (RIBP). Dose to the plexus was assessed by a retrospective delineation of the brachial plexus on the CT used for treatment planning. Then, D_max, D_0.1cc, D_1cc and D_3.0cc of the brachial plexus were collected from the dose-volume histograms (DVH) and recalculated to the biologically effective dose (BED) using α/β = 3 Gy. A normal tissue complication probability (NTCP) model, based on four different dose-volume parameters (BED_3,max, BED_3,0.1cc, BED_3,1.0cc, BED_3,3.0cc) was fitted to the data.

Results: Fifty-two patients with 56 apically located tumors were identified. Median prescription dose per fraction was 15 Gy (range 6–17) and median number of fractions was 3 (3–10). With a median follow-up of 30 months (6.1–72) seven patients experienced maximum grade 2 (scored 3 times) or 3 (scored 4 times) RIBP after a median of 8.7 months (range 4.0–31). Three patients had combined symptoms with pain, sensory and motor affection and four patients had isolated pain. Median BED_3,max for the patients experiencing RIBP was 381 Gy (range 30–524) versus BED_3,max of 34 Gy (range 0.10–483) for the patients without RIBP. The NTCP models showed a very high predictive ability (area under the receiver operating characteristic curve (AUC) 0.80–0.88).

Conclusion: SBRT of apically located lung lesions may cause severe neurological symptoms; for a three-fraction treatment, we suggest that the maximum dose to the plexus should be kept ≤30 Gy (130 Gy BED₃).

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The study was supported by the Funds of Radiumhemmet Stockholm, the ALF-funds, the Swedish Cancer Society, the Swedish Radiation Safety Authority and the Swedish National Board of Health and Welfare.